Table 2. Multivariate analyses used to... | American Society of Hematology

Table 2.

Multivariate analyses used to determine the prognostic significance of FLT3-ITD MRD^neg at various landmarks

Clinical and genetic variables	CIR		OS
Clinical and genetic variables	HR (95% CI)	P	HR (95% CI)	P
Landmark	Cy2 (n = 142)
Age (10 y-increase)	0.95 (0.71-1.27)	.727	1.42 (1.07-1.89)	.017
Female	0.61 (0.32-1.15)	.123	0.63 (0.36-1.09)	.097
WBC (log₁₀)	1.18 (0.69-2.05)	.534	0.68 (0.38-1.23)	.200
BM blasts	1.00 (0.98-1.02)	.890	1.00 (0.99-1.02)	.684
NPM1^mut	0.31 (0.14-0.68)	.005	0.85 (0.45-1.59)	.599
FLT3-ITD^high	1.02 (0.52-2.01)	.948	1.12 (0.61-2.07)	.711
HCT in CR1∗	0.13 (0.05-0.30)	<.001	0.64 (0.37-1.12)	.117
FLT3-ITD MRD^neg	0.29 (0.13-0.69)	.006	0.39 (0.18-0.85)	.018
Landmark	EOT (n = 116)
Age (10 y-increase)	0.98 (0.71-1.36)	.900	1.73 (1.27-2.35)	<.001
Female	0.61 (0.30-1.25)	.175	0.64 (0.36-1.14)	.127
WBC (log₁₀)	1.10 (0.61-2.00)	.743	0.82 (0.49-1.37)	.448
BM blasts	1.00 (0.98-1.02)	.955	0.99 (0.98-1.01)	.354
NPM1^mut	0.32 (0.14-0.76)	.009	0.82 (0.42-1.60)	.568
FLT3-ITD^high	1.03 (0.45-2.36)	.948	0.96 (0.50-1.85)	.901
HCT in CR1∗	0.19 (0.08-0.44)	<.001	0.59 (0.30-1.17)	.130
FLT3-ITD MRD^neg	0.34 (0.09-1.20)	.093	0.30 (0.09-0.98)	.046
Landmark	FU (3-12 mo) (n = 148)
Age (10 y-increase)	1.03 (0.80-1.35)	.826	1.24 (0-95-1.629)	.109
Female	0.48 (0.24-0.95)	.035	0.62 (0.35-1.11)	.107
WBC (log₁₀)	0.74 (0.40-1.354)	.321	0.69 (0.40-1.19)	.180
BM blasts	1.00 (0.99-1.02)	.749	1.00 (0.99-1.02)	.626
NPM1^mut	0.53 (0.25-1.12)	.094	0.95 (0.47-1.90)	.879
FLT3-ITD^high	1.12 (0.52-2.39)	.774	0.99 (0.51-1.93)	.9477
HCT in CR1	0.12 (0.05-0.32)	<.001	0.81 (0.40-1.62)	.541
FLT3-ITD MRD^neg	1		1
FLT3-ITD MRD^conv^_FU	16.64 (6.52-42.48)	<.001	4.05 (1.78-9.18)	<.001
FLT3-ITD MRD^pers	51.98 (14.75-183.15)	<.001	3.69 (1.26-10.82)	.017

Clinical and genetic variables	CIR		OS
Clinical and genetic variables	HR (95% CI)	P	HR (95% CI)	P
Landmark	Cy2 (n = 142)
Age (10 y-increase)	0.95 (0.71-1.27)	.727	1.42 (1.07-1.89)	.017
Female	0.61 (0.32-1.15)	.123	0.63 (0.36-1.09)	.097
WBC (log₁₀)	1.18 (0.69-2.05)	.534	0.68 (0.38-1.23)	.200
BM blasts	1.00 (0.98-1.02)	.890	1.00 (0.99-1.02)	.684
NPM1^mut	0.31 (0.14-0.68)	.005	0.85 (0.45-1.59)	.599
FLT3-ITD^high	1.02 (0.52-2.01)	.948	1.12 (0.61-2.07)	.711
HCT in CR1∗	0.13 (0.05-0.30)	<.001	0.64 (0.37-1.12)	.117
FLT3-ITD MRD^neg	0.29 (0.13-0.69)	.006	0.39 (0.18-0.85)	.018
Landmark	EOT (n = 116)
Age (10 y-increase)	0.98 (0.71-1.36)	.900	1.73 (1.27-2.35)	<.001
Female	0.61 (0.30-1.25)	.175	0.64 (0.36-1.14)	.127
WBC (log₁₀)	1.10 (0.61-2.00)	.743	0.82 (0.49-1.37)	.448
BM blasts	1.00 (0.98-1.02)	.955	0.99 (0.98-1.01)	.354
NPM1^mut	0.32 (0.14-0.76)	.009	0.82 (0.42-1.60)	.568
FLT3-ITD^high	1.03 (0.45-2.36)	.948	0.96 (0.50-1.85)	.901
HCT in CR1∗	0.19 (0.08-0.44)	<.001	0.59 (0.30-1.17)	.130
FLT3-ITD MRD^neg	0.34 (0.09-1.20)	.093	0.30 (0.09-0.98)	.046
Landmark	FU (3-12 mo) (n = 148)
Age (10 y-increase)	1.03 (0.80-1.35)	.826	1.24 (0-95-1.629)	.109
Female	0.48 (0.24-0.95)	.035	0.62 (0.35-1.11)	.107
WBC (log₁₀)	0.74 (0.40-1.354)	.321	0.69 (0.40-1.19)	.180
BM blasts	1.00 (0.99-1.02)	.749	1.00 (0.99-1.02)	.626
NPM1^mut	0.53 (0.25-1.12)	.094	0.95 (0.47-1.90)	.879
FLT3-ITD^high	1.12 (0.52-2.39)	.774	0.99 (0.51-1.93)	.9477
HCT in CR1	0.12 (0.05-0.32)	<.001	0.81 (0.40-1.62)	.541
FLT3-ITD MRD^neg	1		1
FLT3-ITD MRD^conv^_FU	16.64 (6.52-42.48)	<.001	4.05 (1.78-9.18)	<.001
FLT3-ITD MRD^pers	51.98 (14.75-183.15)	<.001	3.69 (1.26-10.82)	.017

FLT3-ITD^high, FLT3-internal tandem duplication with AR ≥0.5; MRD^conv^_FU, conversion from MRD negative at the last previously assessed time point to MRD positive at the time point FU; MRD^pers, persistent MRD^pos.

∗

As time-dependent variable.

View Large